Accendra Health, Inc. (ACH) Earnings
Accendra Health, Inc. is expected to report next earnings on October 29, 2026 (in NaN days), with a consensus EPS estimate of $-0.05. ACH has beaten EPS estimates in 10 of its last 12 reported quarters (average surprise -22.3% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 10, 2026 | $-0.08 | $-0.19 | -126.6% | $613M | -2.5% |
| May 11, 2026 | $-0.06 | $-0.04 | +33.3% | $628M | -2.5% |
| Feb 19, 2026 | $0.22 | $0.21 | -4.5% | $709M | +9.5% |
| Oct 30, 2025 | $0.23 | $0.25 | +8.7% | $697M | -2.5% |
| May 8, 2025 | $0.20 | $0.23 | +15.0% | $2.6B | -3.8% |
| Feb 28, 2025 | $0.53 | $0.55 | +3.8% | $2.7B | +0.8% |
| Aug 2, 2024 | $0.33 | $0.36 | +10.1% | $2.7B | +0.9% |
| May 3, 2024 | $0.17 | $0.19 | +11.8% | $2.6B | +0.1% |
| Feb 20, 2024 | $0.68 | $0.69 | +1.5% | $2.7B | -0.4% |
| Nov 3, 2023 | $0.35 | $0.44 | +23.9% | $2.6B | +0.6% |
| Aug 4, 2023 | $0.16 | $0.18 | +10.4% | $2.6B | +2.8% |
| May 5, 2023 | $-0.09 | $0.05 | +155.6% | $2.5B | +4.9% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q2 FY2026 · August 10, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
Leadership Transition - CEO Ed Pesicka announced his planned retirement by the end of 2026, after nearly eight years leading the company through post-turnaround stabilization, the COVID-19 pandemic, the P&HS segment sale, and recent balance sheet optimization. - The company has a long-standing succession planning process in place, and the board will complete a thoughtful transition to position the new CEO for long-term value creation. Commercial & Strategic Milestones - Formally executed the renewal of the largest soft goods contract with the company's largest commercial payer, providing multi-year stability for a core portion of the commercial payer portfolio. - Signed a new sole-source agreement with a regional health system expected to launch in early 2027. - Executed a new enterprise-wide fee-for-service agreement with another payer expected to drive additional patient volume, improve capacity utilization, and create mutual value. - Continued national rollout of the Sleep Center of Excellence program, which is on track to contribute to growth and profitability starting in late 2026. - Completed balance sheet optimization in June 2026, reducing total debt by almost $400 million since the end of March 2026, extending the weighted average life of debt to nearly 5.5 years with no maturities until 2029, and maintaining ample liquidity. Operational & Cost Initiatives - After completing separation from Owens & Minor and exiting the large commercial payer in Q1, the company already eliminated over $125 million in annualized costs by early 2026. - A planned pause on additional cost reductions to allow business stabilization after major structural changes is now complete; the next phase of targeted cost reductions was launched one month into Q3 2026, with additional opportunities to be evaluated in coming months. - The company is pursuing new third-party logistics arrangements for inventory management and fulfillment across select product categories, expected to go live in late 2026 to lower operating costs, reduce inventory, and improve cash flow. - Targeted organizational changes have been made to commercial and operational teams to improve customer responsiveness, strengthen execution, and reinvigorate the sales force. Challenges in Q2 2026 - Q2 2026 financial results missed internal expectations, driven by three main factors: revenue growth below forecast, delayed timing of planned cost reductions, and slower-than-expected recovery of collection rates. - Collections from payers remained below historical norms, driven by technology implementation growing pains and a recent unprecedented spike in payer audit volume that pulled resources from other initiatives and delayed collections. Mitigation plans are in place and progress is encouraging.
Guidance
- Full year 2026 revenue guidance was revised downward to a range of $2.45 billion to $2.55 billion, from prior guidance, due to Q2 underperformance and delayed benefits from cost savings and growth initiatives. - Full year 2026 adjusted EBITDA guidance was revised downward to a range of $300 million to $320 million, from prior guidance. - Full year 2026 pre-cash flow fully levered free cash flow is now expected to be breakeven to slightly positive, due to the adjusted EBITDA outlook and incremental cash interest costs from the balance sheet optimization. - Management expects Q4 2026 to be much stronger than Q3 2026, serving as a strong launchpad for 2027 performance. The company maintains confidence that the business can generate ~$100 million in annual free cash flow in a normalized operating environment. - The company expects to launch a small at-the-market (ATM) equity program in the near term, with proceeds to be used for debt reduction to support ongoing deleveraging. - A Net Operating Loss (NOL) rights plan will be implemented to protect the company's over $200 million in net operating loss carryforwards from inadvertent forfeiture due to ownership change rules.
Segment performance
Overall Q2 2026 revenue (excluding the exited large commercial payer impact) grew 2% year-over-year, an improvement from prior quarters. By product segment: - Sleep: 5.5% mid-single-digit year-over-year growth, with marked improvement in sleep equipment and continued strong growth in sleep supplies; this category drove the overall revenue improvement in the quarter. - Diabetes: 4% year-over-year growth, a 500 basis point improvement from Q1 2026, with strong growth in insulin pumps partially offset by weakness in CGM. - Respiratory & Wound: Still in recovery, down year-over-year. - Ostomy & Urology: Continued strong growth, posting high single-digit year-over-year growth rates. Overall adjusted EBITDA for Q2 2026 was just over $60 million, with a small margin rate improvement compared to Q1 2026. Adjusted EBITDA less patient service equipment (PSC) CapEx was $16.3 million, down slightly from Q1 due to higher PSC CapEx tied to an improved outlook for future sleep patient starts.
Risks & headwinds
- Slower-than-expected recovery of payer collection rates negatively impacted adjusted EBITDA by ~$10 million in Q2 2026 and ~$20 million in the first half of 2026, and resolution is taking longer than initially anticipated. - An unprecedented spike in audit volume from multiple large commercial payers, outside of normal industry levels, has temporarily delayed collections and diverted operational resources from automation and other improvement projects. - Underperformance in the respiratory and wound product categories continues to weigh on overall top-line growth. - Operating expenses as a percentage of revenue remain above historical levels, dragging on adjusted EBITDA, and benefits from cost reduction initiatives were delayed to the second half of 2026. - Inadvertent changes in shareholder ownership could jeopardize the value of the company's over $200 million in net operating loss carryforwards under complex IRS rules, if unaddressed.
Analyst Q&A
Q: Can you explain the unusual payer collection headwind, confirm there are no unexpected supplier contract issues, and clarify if Q4 2026 will represent a normalized run rate for 2027? /
A: The company has no supplier contracts that have been terminated unexpectedly, and maintains proactive advance planning for all upcoming contract renewals. The collection issue stems from an unprecedented exponential increase in audit items from multiple large commercial payers, which delayed payments and pulled staff from collections automation work. Management expects Q4 2026 to be a strong foundational quarter for 2027, with benefits from new commercial contracts, organizational changes, cost reductions, and resolved collection issues expected to flow into full-year 2027 results.
Q: What portions of the Q4 2026 improvement are within the company's control, and why is the NOL rights plan being implemented now? /
A: Cost reduction execution, speed of contract implementation for new agreements, logistics partnership rollout, and general commercial execution are all core levers the company controls to drive improvement. The plan was initiated now because it was identified as a proactive step during the recent balance sheet optimization, and recent increases in large shareholder positions brought the company halfway to the ownership threshold that would risk forfeiture of the NOL value under IRS rules, making it a prudent time to protect shareholder value.
Q: Why was there a pause in cost reduction efforts earlier in 2026, and what are the non-core assets being sold? /
A: The pause was not tied to the payer audit issue; instead, it came after the company removed more than $125 million in annualized costs, including costs tied to the exited large payer contract and stranded costs from prior transactions. Management paused to let the business stabilize after the major structural changes of separation from Owens & Minor and the payer exit to avoid operational disruption. The non-core assets are small, legacy businesses unrelated to the current core home healthcare focus that were retained after prior divestitures, and the company received attractive unsolicited offers for them.
Q: What is the pacing of free cash flow improvement in H2 2026, will the company need to rely on the revolving credit facility, and will 2027 be a normalized year hitting the $100 million free cash flow target? /
A: After debt reduction from the balance sheet optimization, low cash balances are expected, with occasional draws on the revolver for working capital lumpiness, but no consistent meaningful draw like in prior periods. Only one material transaction cost remains, due in Q1 2027, and all operational improvements launched in 2026 will be fully baked into the 2027 run rate, putting the company on track for a normalized year in 2027.